The DOI matches its Crossref record; 188 of the 188 references it cites were found in a registry or an index.
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Open accessAbstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming a global health problem. Cardiovascular diseases (CVD) are the most common cause of mortality in NAFLD patients. NAFLD and CVD share several common risk factors including obesity, insulin resistance, and type 2 diabetes (T2D). Atherogenic dyslipidemia, characterized by plasma hypertriglyceridemia, increased small dense low-density lipoprotein (LDL) particles, and decreased high-density lipoprotein cholesterol (HDL-C) levels, is often observed in NAFLD patients. SCOPE OF REVIEW: In this review, we highlight recent epidemiological studies evaluating the link between NAFLD and CVD risk. We further focus on recent mechanistic insights into the links between NAFLD and altered lipoprotein metabolism. We also discuss current therapeutic strategies for NAFLD and their potential impact on NAFLD-associated CVD risk. MAJOR CONCLUSIONS: Alterations in hepatic lipid and lipoprotein metabolism are major contributing factors to the increased CVD risk in NAFLD patients, and many promising NASH therapies in development also improve dyslipidemia in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Interestingly, the GLP1 receptor (GLP1-R) agonists liraglutide [183] and semaglutide [184] both reduce CVD risk in T2D patients.”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Interestingly, the GLP1 receptor (GLP1-R) agonists liraglutide [183] and semaglutide [184] both reduce CVD risk in T2D patients.”
BackgroundDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0106-z · Cited by 3,211
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Association between insulin resistance and the development of cardiovascular disease
Ormazabal, V., Nair, S., Elfeky, O., Aguayo, C., Salomon, C., & Zuñiga, F. A. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0762-4 · Cited by 2,280
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
van der Veen, J. N., Kennelly, J. P., Wan, S., Vance, J. E., Vance, D. E., & Jacobs, R. L. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.04.006 · Cited by 1,514
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,424
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234 · cited 6×
“For example, mutations in several genes involved in the control of lipid metabolism (for example, patatin-like phospholipase domain containing 3, PNPLA3 [4], transmembrane 6 superfamily member 2, TM6SF2 [5], farnesyl-diphosphate farnesyltransferase 1, FDFT1 [6], and membrane bound O-acyltransferase domain containing 7…”
BackgroundInfluentialPioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124 · cited 1×
“While long-term rosiglitazone treatment of T2D patients may slightly increase the risk of myocardial infarction [164], pioglitazone somewhat decreases the risk of MACE (although the risk of heart failure increases with all glitazones) [165,166].”
BackgroundLoss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Lambert, J. E., Ramos–Roman, M. A., Browning, J. D., & Parks, E. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.049 · Cited by 1,069 · cited 11×
“Importantly, the molar ratio of VLDL-TG (particle TG content) to VLDL-ApoB100 (the number of particles) is elevated in nondiabetic obese individuals with high intrahepatic TG (measured by MRS), suggesting that the secreted VLDL particles are larger and resemble the pro-atherogenic VLDL1 [65].”
BackgroundInfluentialRatziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Self-citationCusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024 · cited 1×
“Conversely, pioglitazone treatment resulted in similar plasma lipid improvements in biopsy-proven NASH patients as observed in subjects with T2D [159,167].”
Speliotes, E. K., Yerges-Armstrong, L. M., Wu, J., Hernaez, R., Kim, L. J., Palmer, C. D., Gudnason, V., Eiriksdottir, G., Garcia, M. E., Launer, L. J., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001324 · Cited by 984
Chávez-Talavera, O., Tailleux, A., Lefebvre, P., & Staels, B. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.01.055 · Cited by 970
Self-citationWeight and Metabolic Outcomes 12 Years after Gastric Bypass
Adams, T. D., Davidson, L. E., Litwin, S. E., Kim, J., Kolotkin, R. L., Nanjee, M. N., Gutierrez, J. M., Frogley, S. J., Ibele, A. R., Brinton, E. A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700459 · Cited by 956
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Richardson, T. G., Sanderson, E., Palmer, T. M., Ala-Korpela, M., Ference, B. A., Davey Smith, G., & Holmes, M. V. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003062 · Cited by 843
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820
Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802
Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 795
Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease
Smith, G. I., Shankaran, M., Yoshino, M., Schweitzer, G. G., Chondronikola, M., Beals, J. W., Okunade, A. L., Patterson, B. W., Nyangau, E., Field, T., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134165 · Cited by 771 · cited 10×
“Importantly, the molar ratio of VLDL-TG (particle TG content) to VLDL-ApoB100 (the number of particles) is elevated in nondiabetic obese individuals with high intrahepatic TG (measured by MRS), suggesting that the secreted VLDL particles are larger and resemble the pro-atherogenic VLDL1 [65].”
BackgroundInfluentialBariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients
Lassailly, G., Caiazzo, R., Buob, D., Pigeyre, M., Verkindt, H., Labreuche, J., Raverdy, V., Leteurtre, E., Dharancy, S., Louvet, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.014 · Cited by 762
Li, Z., Agellon, L. B., Allen, T. M., Umeda, M., Jewell, L., Mason, A., & Vance, D. E. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.03.007 · Cited by 752
Mancina, R. M., Dongiovanni, P., Petta, S., Pingitore, P., Meroni, M., Rametta, R., Borén, J., Montalcini, T., Pujia, A., Wiklund, O., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.032 · Cited by 676
Fabbrini, E., Mohammed, B. S., Magkos, F., Korenblat, K. M., Patterson, B. W., & Klein, S. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.11.038 · Cited by 631
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625
Lassailly, G., Caiazzo, R., Ntandja-Wandji, L.-C., Gnemmi, V., Baud, G., Verkindt, H., Ningarhari, M., Louvet, A., Leteurtre, E., Raverdy, V., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.06.006 · Cited by 622 · cited 1×
“com progressively decrease histological fibrosis in NASH patients [128].”
BackgroundMcGarry, J. D., Leatherman, G. F., & Foster, D. W. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34693-8 · Cited by 600
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Mantovani, A., Scorletti, E., Mosca, A., Alisi, A., Byrne, C. D., & Targher, G. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154170 · Cited by 553
Sanyal, A., Charles, E. D., Neuschwander-Tetri, B. A., Loomba, R., Harrison, S. A., Abdelmalek, M. F., Lawitz, E. J., Halegoua-DeMarzio, D., Kundu, S., Noviello, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31785-9 · Cited by 550
Exome-wide association study of plasma lipids in >300,000 individuals
Charge Diabetes Working Group, Liu, D. J., The EPIC-InterAct Consortium, EPIC-CVD Consortium, GOLD Consortium, Program, V. M. V., Peloso, G. M., Yu, H., Butterworth, A. S., Wang, X., et al. (2017) · Nature Genetics · doi:10.1038/ng.3977 · Cited by 540
Dongiovanni, P., Petta, S., Maglio, C., Fracanzani, A. L., Pipitone, R., Mozzi, E., Motta, B. M., Kaminska, D., Rametta, R., Grimaudo, S., et al. (2015) · Hepatology · doi:10.1002/hep.27490 · Cited by 533
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509 · cited 1×
“In Western diet-fed ApoE or LDLR-deficient mice, both liraglutide and semaglutide decrease atherosclerosis through anti-inflammatory effects independent of cholesterol lowering and weight loss [185].”
BackgroundAminian, A., Zajichek, A., Arterburn, D. E., Wolski, K. E., Brethauer, S. A., Schauer, P. R., Kattan, M. W., & Nissen, S. E. (2019) · JAMA · doi:10.1001/jama.2019.14231 · Cited by 505 · cited 1×
“Importantly, bariatric surgery also reduced CVD events and mortality [134] among T2D and obese patients.”
BackgroundJørgensen, A. B., Frikke-Schmidt, R., West, A. S., Grande, P., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs431 · Cited by 501
Anstee, Q. M., Darlay, R., Cockell, S., Meroni, M., Govaere, O., Tiniakos, D., Burt, A. D., Bedossa, P., Palmer, J., Liu, Y.-L., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.003 · Cited by 499
The Role of Cholesterol in the Pathogenesis of NASH
Ioannou, G. N. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.11.008 · Cited by 498
Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497
ANGPTL3 deficiency and protection against coronary artery disease
Stitziel, N. O., Khera, A. V., Wang, X., Bierhals, A. J., Vourakis, A. C., Sperry, A. E., Natarajan, P., Klarin, D., Emdin, C. A., Zekavat, S. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.030 · Cited by 467 · cited 4×
“In line, decreased plasma levels of ANGPTL8 [80] and ANGPTL3 [81] are both associated with decreased CVD risk (defined by the presence of atherosclerotic plaques or myocardial infarction).”
BackgroundInfluentialSmall Dense Low‐Density Lipoprotein as Biomarker for Atherosclerotic Diseases
Ivanova, E. A., Myasoedova, V. A., Melnichenko, A. A., Grechko, A. V., & Orekhov, A. N. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1273042 · Cited by 457
Mardinoglu, A., Wu, H., Bjornson, E., Zhang, C., Hakkarainen, A., Räsänen, S. M., Lee, S., Mancina, R. M., Bergentall, M., Pietiläinen, K. H., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.01.005 · Cited by 453
Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9607 · Cited by 449
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease
Petersen, K. F., Dufour, S., Hariri, A., Nelson-Williams, C., Foo, J. N., Zhang, X.-M., Dziura, J., Lifton, R. P., & Shulman, G. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907295 · Cited by 428
Harrison, S. A., Rinella, M. E., Abdelmalek, M. F., Trotter, J. F., Paredes, A. H., Arnold, H. L., Kugelmas, M., Bashir, M. R., Jaros, M. J., Ling, L., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30474-4 · Cited by 425
Kim, C.-W., Addy, C., Kusunoki, J., Anderson, N. N., Deja, S., Fu, X., Burgess, S. C., Li, C., Ruddy, M., Chakravarthy, M., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.009 · Cited by 419
DeLong, C. J., Shen, Y.-J., Thomas, M. J., & Cui, Z. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.42.29683 · Cited by 416
Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease
Haas, J. T., Francque, S., & Staels, B. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105331 · Cited by 394
Self-citationDistinct but complementary contributions of PPAR isotypes to energy homeostasis
Dubois, V., Eeckhoute, J., Lefebvre, P., & Staels, B. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88894 · Cited by 383
Self-citationRatziu, V., Charlotte, F., Bernhardt, C., Giral, P., Halbron, M., LeNaour, G., Hartmann-Heurtier, A., Bruckert, E., & Poynard, T. (2010) · Hepatology · doi:10.1002/hep.23270 · Cited by 366
Francque, S., Verrijken, A., Caron, S., Prawitt, J., Paumelle, R., Derudas, B., Lefebvre, P., Taskinen, M.-R., Van Hul, W., Mertens, I., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.019 · Cited by 357
Self-citationPatel, K., Harrison, S. A., Elkhashab, M., Trotter, J. F., Herring, R., Rojter, S. E., Kayali, Z., Wong, V. W., Greenbloom, S., Jayakumar, S., et al. (2020) · Hepatology · doi:10.1002/hep.31205 · Cited by 347
Loomba, R., Kayali, Z., Noureddin, M., Ruane, P., Lawitz, E. J., Bennett, M., Wang, L., Harting, E., Tarrant, J. M., McColgan, B. J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.027 · Cited by 340
Nordestgaard, B. G., Wootton, R., & Lewis, B. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.4.534 · Cited by 334
Wu, S., Wu, F., Ding, Y., Hou, J., Bi, J., & Zhang, Z. (2016) · Scientific Reports · doi:10.1038/srep33386 · Cited by 318
Chalasani, N., Guo, X., Loomba, R., Goodarzi, M. O., Haritunians, T., Kwon, S., Cui, J., Taylor, K. D., Wilson, L., Cummings, O. W., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.07.057 · Cited by 315
Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by Pioglitazone
Sakamoto, J., Kimura, H., Moriyama, S., Odaka, H., Momose, Y., Sugiyama, Y., & Sawada, H. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3868 · Cited by 313
The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state
Hodson, L., & Gunn, P. J. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0256-9 · Cited by 309
Holmen, O. L., Zhang, H., Fan, Y., Hovelson, D. H., Schmidt, E. M., Zhou, W., Guo, Y., Zhang, J., Langhammer, A., Løchen, M.-L., et al. (2014) · Nature Genetics · doi:10.1038/ng.2926 · Cited by 302
PPARs and nonalcoholic fatty liver disease
Liss, K. H. H., & Finck, B. N. (2017) · Biochimie · doi:10.1016/j.biochi.2016.11.009 · Cited by 275
Lin, Z., Pan, X., Wu, F., Ye, D., Zhang, Y., Wang, Y., Jin, L., Lian, Q., Huang, Y., Ding, H., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.015308 · Cited by 271
Fibroblast Growth Factor 21—Metabolic Role in Mice and Men
Staiger, H., Keuper, M., Berti, L., Hrabě de Angelis, M., & Häring, H.-U. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00016 · Cited by 270
Harrison, S. A., Rossi, S. J., Paredes, A. H., Trotter, J. F., Bashir, M. R., Guy, C. D., Banerjee, R., Jaros, M. J., Owers, S., Baxter, B. A., et al. (2020) · Hepatology · doi:10.1002/hep.30590 · Cited by 262
Nagashima, M., Watanabe, T., Terasaki, M., Tomoyasu, M., Nohtomi, K., Kim-Kaneyama, J., Miyazaki, A., & Hirano, T. (2011) · Diabetologia · doi:10.1007/s00125-011-2241-2 · Cited by 259 · cited 1×
“Moreover, GLP1 may prevent macrophage foam cell formation [186].”
BackgroundLuukkonen, P. K., Dufour, S., Lyu, K., Zhang, X.-M., Hakkarainen, A., Lehtimäki, T. E., Cline, G. W., Petersen, K. F., Shulman, G. I., & Yki-Järvinen, H. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922344117 · Cited by 249
Baratta, F., Pastori, D., Angelico, F., Balla, A., Paganini, A. M., Cocomello, N., Ferro, D., Violi, F., Sanyal, A. J., & Del Ben, M. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.12.026 · Cited by 248
Le, T.-A., Chen, J., Changchien, C., Peterson, M. R., Kono, Y., Patton, H., Cohen, B. L., Brenner, D., Sirlin, C., & Loomba, R. (2012) · Hepatology · doi:10.1002/hep.25731 · Cited by 243
Caiazzo, R., Lassailly, G., Leteurtre, E., Baud, G., Verkindt, H., Raverdy, V., Buob, D., Pigeyre, M., Mathurin, P., & Pattou, F. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000945 · Cited by 226
Lauridsen, B. K., Stender, S., Kristensen, T. S., Kofoed, K. F., Køber, L., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx662 · Cited by 213
Haas, J. T., Miao, J., Chanda, D., Wang, Y., Zhao, E., Haas, M. E., Hirschey, M., Vaitheesvaran, B., Farese, R. V., Kurland, I. J., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.05.002 · Cited by 210
Self-citationGehrke, N., & Schattenberg, J. M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.020 · Cited by 209
Jain, M. R., Giri, S. R., Bhoi, B., Trivedi, C., Rath, A., Rathod, R., Ranvir, R., Kadam, S., Patel, H., Swain, P., et al. (2018) · Liver International · doi:10.1111/liv.13634 · Cited by 206
Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis
Wang, X., Cai, B., Yang, X., Sonubi, O. O., Zheng, Z., Ramakrishnan, R., Shi, H., Valenti, L., Pajvani, U. B., Sandhu, J., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.03.010 · Cited by 204
Bril, F., Kalavalapalli, S., Clark, V. C., Lomonaco, R., Soldevila-Pico, C., Liu, I.-C., Orsak, B., Tio, F., & Cusi, K. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.12.001 · Cited by 199
Gan, L. T., Van Rooyen, D. M., Koina, M. E., McCuskey, R. S., Teoh, N. C., & Farrell, G. C. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.024 · Cited by 198
Contribution of remnant cholesterol to cardiovascular risk
Langsted, A., Madsen, C. M., & Nordestgaard, B. G. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13059 · Cited by 189
Thyroid hormone signaling and the liver
Ritter, M. J., Amano, I., Hollenberg, A. N., et al. (2020) · Hepatology · doi:10.1002/hep.31296 · Cited by 188 · cited 1×
“TR-b agonism also favors LDLR-mediated endocytosis and reverse cholesterol transport [180].”
BackgroundLiu, Y., Zhong, G.-C., Tan, H.-Y., Hao, F.-B., & Hu, J.-J. (2019) · Scientific Reports · doi:10.1038/s41598-019-47687-3 · Cited by 176
Pirola, C. J., & Sookoian, S. (2015) · Hepatology · doi:10.1002/hep.28142 · Cited by 172
Bril, F., Sninsky, J. J., Baca, A. M., Superko, H. R., Portillo Sanchez, P., Biernacki, D., Maximos, M., Lomonaco, R., Orsak, B., Suman, A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3111 · Cited by 168
Advances in HDL: Much More than Lipid Transporters
Ben‐Aicha, S., Badimón, L., & Vilahur, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030732 · Cited by 168
Chang, Y., Ryu, S., Sung, K.-C., Cho, Y. K., Sung, E., Kim, H.-N., Jung, H.-S., Yun, K. E., Ahn, J., Shin, H., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317666 · Cited by 164
Liver fat accumulation is associated with circulating PCSK9
Ruscica, M., Ferri, N., Macchi, C., Meroni, M., Lanti, C., Ricci, C., Maggioni, M., Fracanzani, A. L., Badiali, S., Fargion, S. R., et al. (2016) · Annals of Medicine · doi:10.1080/07853890.2016.1188328 · Cited by 163
Sinn, D. H., Kang, D., Chang, Y., Ryu, S., Gu, S., Kim, H., Seong, D., Cho, S. J., Yi, B.-K., Park, H.-D., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-311854 · Cited by 163
Simón, J., Núñez-García, M., Fernández‐Tussy, P., Barbier‐Torres, L., Fernández‐Ramos, D., Gómez‐Santos, B., Buqué, X., Lopitz‐Otsoa, F., Goikoetxea‐Usandizaga, N., Serrano‐Maciá, M., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.01.013 · Cited by 163
Caron, S., Verrijken, A., Mertens, I., Samanez, C. H., Mautino, G., Haas, J. T., Duran-Sandoval, D., Prawitt, J., Francque, S., Vallez, E., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.220723 · Cited by 162
Self-citationHuman PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids
Luukkonen, P. K., Nick, A., Hölttä-Vuori, M., Thiele, C., Isokuortti, E., Lallukka-Brück, S., Zhou, Y., Hakkarainen, A., Lundbom, N., Peltonen, M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127902 · Cited by 161
Fibrates and future PPARα agonists in the treatment of cardiovascular disease
Staels, B., Maes, M., & Zambon, A. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1278 · Cited by 160
Self-citationPockros, P. J., Fuchs, M., Freilich, B., Schiff, E., Kohli, A., Lawitz, E. J., Hellstern, P. A., Owens‐Grillo, J., Van Biene, C., Shringarpure, R., et al. (2019) · Liver International · doi:10.1111/liv.14209 · Cited by 160
Roumans, K. H. M., Lindeboom, L., Veeraiah, P., Remie, C. M. E., Phielix, E., Havekes, B., Bruls, Y. M. H., Brouwers, M. C. G. J., Ståhlman, M., Alssema, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15684-0 · Cited by 159
Self-citationBays, H. E., Schwartz, S. L., Littlejohn, T. W., Kerzner, B., Krauss, R. M., Karpf, D. B., Choi, Y., Wang, X., Naim, S., & Roberts, B. K. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1061 · Cited by 157
Grimaudo, S., Pipitone, R. M., Pennisi, G., Celsa, C., Cammà, C., Marco, V. D., Barcellona, M. R., Boemi, R., Enea, M., Giannetti, A., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.08.011 · Cited by 156
Lee, S. B., Park, G., Lee, J., Lee, B. U., Park, J. H., Kim, B. G., Jung, S. W., Jeong, I. D., Bang, S. J., Shin, J. W., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.12.012 · Cited by 155
Advances in lipid-lowering therapy through gene-silencing technologies
Nordestgaard, B. G., Nicholls, S. J., Langsted, A., Ray, K. K., & Tybjærg‐Hansen, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2018.3 · Cited by 155
Haas, J. T., Vonghia, L., Mogilenko, D. A., Verrijken, A., Molendi-Coste, O., Fleury, S., Deprince, A., Nikitin, A., Woitrain, E., Ducrocq-Geoffroy, L., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0076-1 · Cited by 155
Self-citationImpact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis
Siddiqui, M. S., Natta, M. L. V., Connelly, M. A., Vuppalanchi, R., Neuschwander‐Tetri, B. A., Tonascia, J., Guy, C. D., Loomba, R. S., Dasarathy, S., Wattacheril, J. J., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.006 · Cited by 147
Chen, Y. Q., Pottanat, T. G., Siegel, R. W., Ehsani, M., Qian, Y.-W., Zhen, E. Y., Regmi, A., Roell, W. C., Guo, H., Luo, M. J., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra120000781 · Cited by 147
de Jong, M., van der Worp, H. B., van der Graaf, Y., Visseren, F. L. J., & Westerink, J. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0617-4 · Cited by 141
NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects
Sliz, E., Sebert, S. P., Würtz, P., Kangas, A. J., Soininen, P., Lehtimäki, T. J., Kähönen, M. A. P., Viikari, J. S. A., Männikkö, M., Ala‐Korpela, M., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy124 · Cited by 139
Manco, M., Mosca, A., PEPPO, F. D., Caccamo, R., Cutrera, R., Giordano, U., Stefanis, C. D., Alisi, A., Baumann, U., Silecchia, G., et al. (2016) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2016.08.101 · Cited by 137
Fibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives
Somm, E., & Jornayvaz, F. R. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00134 · Cited by 135
Orasanu, G., Ziouzenkova, O., Devchand, P. R., Nehra, V., Hamdy, O., Horton, E. S., & Plutzky, J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.055 · Cited by 131
Thereaux, J., Lesuffleur, T., Czernichow, S., Basdevant, A., Msika, S., Nocca, D., Millat, B., & Fagot‐Campagna, A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30191-3 · Cited by 126
Hashimoto, Y., Hamaguchi, M., Kojima, T., Fukuda, T., Ohbora, A., & Fukui, M. (2017) · Medicine · doi:10.1097/md.0000000000006712 · Cited by 124
Ünalp–Arida, A., & Ruhl, C. E. (2019) · Hepatology · doi:10.1002/hep.31032 · Cited by 123
Zhou, Y., Llauradó, G., Orešič, M., Hyötyläinen, T., Orho‐Melander, M., & Yki‐Järvinen, H. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.010 · Cited by 122
He, P., Jiang, T., Ouyang, X.-P., Liang, Y., Zou, J.-Q., Wang, Y., Shen, Q., Liao, L., & Zheng, X. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.02.006 · Cited by 122
Non‐alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study
Sinn, D. H., Kang, D., Chang, Y., Ryu, S., Cho, S. J., Paik, S. W., Song, Y. B., Pastor‐Barriuso, R., Güallar, E., Cho, J., et al. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14856 · Cited by 121
Lee, Y., Lee, S., Lee, C. J., Kim, S. H., Song, Y.-M., Yoon, M. R., Jeon, B. H., Lee, J. H., Lee, B., Kang, E. S., et al. (2016) · Scientific Reports · doi:10.1038/srep24013 · Cited by 120
Zhang, D., Tong, X., VanDommelen, K., Gupta, N., Stamper, K., Brady, G. F., Meng, Z., Lin, J. D., Rui, L., Omary, M. B., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89934 · Cited by 120
Boubia, B., Poupardin, O., Barth, M., Binet, J. L., Peralba, P., Mounier, L., Jacquier, E., Gauthier, E., Lepais, V., Chatar, M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01285 · Cited by 120
Bricambert, J., Alves‐Guerra, M., Estèves, P., Prip‐Buus, C., Bertrand‐Michel, J., Guillou, H., Chang, C. J., Wal, M. N. V., Canonne‐Hergaux, F., Mathurin, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04361-y · Cited by 117
Shojaee-Moradie, F., Cuthbertson, D. J., Barrett, M., Jackson, N. C., Herring, R., Thomas, E. L., Bell, J., Kemp, G. J., Wright, J., & Umpleby, A. M. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2353 · Cited by 116 · cited 2×
“Moreover, these changes were accompanied by improvements in several CVD risk parameters, including decreased plasma LDL-C, increased clearance of large TG-rich VLDL1 particles, improved insulin sensitivity, and reduced arterial stiffness [123].”
BackgroundLaatsch, A., Merkel, M., Talmud, P. J., Grewal, T., Beisiegel†, U., & Heeren, J. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.07.046 · Cited by 111
Abdelbasset, W. K., Tantawy, S. A., Kamel, D. M., Alqahtani, B. A., & Soliman, G. S. (2019) · Medicine · doi:10.1097/md.0000000000014918 · Cited by 109
VLDL triglyceride kinetics in lean, overweight, and obese men and women
Mittendorfer, B., Yoshino, M., Patterson, B. W., & Klein, S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1500 · Cited by 108
PNPLA3, TM6SF2, and MBOAT7 Genotypes and Coronary Artery Disease
Simons, N., Isaacs, A. J., Koek, G. H., Kuč, S., Schaper, N. C., & Brouwers, M. C. G. J. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.020 · Cited by 102
Wallach, J. D., Wang, K., Zhang, A. D., Cheng, D., Nardini, H. K. G., Lin, H., Bracken, M. B., Desai, M. M., Krumholz, H. M., & Ross, J. S. (2020) · BMJ · doi:10.1136/bmj.l7078 · Cited by 101
Bril, F., Portillo Sanchez, P., Lomonaco, R., Orsak, B., Hecht, J., Tio, F., & Cusi, K. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00867 · Cited by 97
Parlevliet, E. T., Wang, Y., Geerling, J. J., Schröder-Van der Elst, J. P., Picha, K., O'Neil, K., Stojanovic-Susulic, V., Ort, T., Havekes, L. M., Romijn, J. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049152 · Cited by 97
Lebeau, P. F., Byun, J. H., Platko, K., Al‐Hashimi, A., Lhoták, Š., MacDonald, M. E., Mejía‐Benítez, A., Prat, A., Igdoura, S. A., Trigatti, B. L., et al. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.10.009 · Cited by 90
Rinella, M. E., Trotter, J. F., Abdelmalek, M. F., Paredes, A. H., Connelly, M. A., Jaros, M. J., Ling, L., Rossi, S. J., DePaoli, A. M., & Harrison, S. A. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.11.032 · Cited by 87
Overexpression of Angiopoietin-Like Protein 4 Protects Against Atherosclerosis Development
Georgiadi, A., Wang, Y., Stienstra, R., Tjeerdema, N., Janssen, A., Stalenhoef, A., van der Vliet, J. A., de Roos, A., Tamsma, J. T., Smit, J. W. A., et al. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301698 · Cited by 86
Nonalcoholic fatty liver disease and statins
Τζιόμαλος, Κ., Athyros, V. G., Paschos, P., & Karagiannis, A. I. (2015) · Metabolism · doi:10.1016/j.metabol.2015.07.003 · Cited by 84
Raj, P., Gomes, R. M., Kumar, S. S., Senthilnathan, P., Karthikeyan, P., Annapoorni, S., & Palanivelu, C. (2015) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2015.02.006 · Cited by 83
Chen, Z., Qin, H., Qiu, S., Chen, G., & Chen, Y. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1104-6 · Cited by 81
Newsome, P. N., Palmer, M., Freilich, B., Sheikh, M. Y., Sheikh, A., Sarles, H., Herring, R., Mantry, P., Kayali, Z., Hassanein, T., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.024 · Cited by 80
Borén, J., Watts, G. F., Adiels, M., Söderlund, S., Chan, D. C., Hakkarainen, A., Lundbom, J., Lundbom, N., Matikainen, N., Kahri, J., et al. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305614 · Cited by 72
Verrijken, A., Beckers, S., Francque, S., Hilden, H., Caron, S., Zegers, D., Ruppert, M., Hubens, G., Marck, E. V., Michielsen, P. P., et al. (2013) · Obesity · doi:10.1002/oby.20366 · Cited by 71
Self-citationYang, M. H., Sung, J., & Gwak, G. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.11.017 · Cited by 69
Lebeau, P. F., Byun, J. H., Platko, K., MacDonald, M. E., Poon, S. V., Faiyaz, M., Seidah, N. G., & Austin, R. C. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008094 · Cited by 67
Kapuria, D., Takyar, V. K., Etzion, O., Surana, P., O’Keefe, J. H., & Koh, C. (2018) · Hepatology Communications · doi:10.1002/hep4.1199 · Cited by 66
Saeed, N., Nadeau, B., Shannon, C., & Tincopa, M. (2019) · Nutrients · doi:10.3390/nu11123064 · Cited by 65
Zheng, J., Zhou, Y., Zhang, K., Qi, Y., An, S., Wang, S., Zhao, X., & Tang, Y. (2018) · BMC Cardiovascular Disorders · doi:10.1186/s12872-018-0877-2 · Cited by 65
Corey, K. E., Vuppalanchi, R., Wilson, L., Cummings, O. W., Chalasani, N., & CRN, T. N. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13035 · Cited by 63
Yilmaz, Y. N., Ulukaya, E., Atuğ, Ö., & Dolar, E. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832b77ae · Cited by 63
Genetic variation in PNPLA3 but not APOC3 influences liver fat in non‐alcoholic fatty liver disease
Hyysalo, J., Stojkovic, I., Kotronen, A., Hakkarainen, A., Sevastianova, K., Makkonen, J., Lundbom, N. M. I., Rissanen, A., Krauss, R. M., Melander, O., et al. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07045.x · Cited by 60
Nakatsuka, A., Matsuyama, M., Yamaguchi, S., Katayama, A., Eguchi, J., Murakami, K., Teshigawara, S., Ogawa, D., Wada, N., Yasunaka, T., et al. (2016) · Scientific Reports · doi:10.1038/srep21721 · Cited by 60
Pastori, D., Baratta, F., Novo, M., Cocomello, N., Violi, F., Angelico, F., & Ben, M. D. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7110378 · Cited by 59
Eren, F., Kurt, R., Ermış, F., Atuğ, Ö., İmeryüz, N., & Yilmaz, Y. N. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.03.019 · Cited by 56
Serum Lipid Abnormalities and Nonalcoholic Fatty Liver Disease in Adult Males
Peng, K., Mo, Z., & Tian, G. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.01.002 · Cited by 54
Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis
Filipova, E. P., Uzunova, K. H., Kalinov, K., & Vekov, T. Y. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0290-5 · Cited by 54
Margerie, D., Lefèbvre, P., Raverdy, V., Schwahn, U., Ruetten, H., Larsen, P. J., Duhamel, A., Labreuche, J., Thuillier, D., Derudas, B., et al. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0536-1 · Cited by 54
Self-citationBrouwers, M. C. G. J., Simons, N., Stehouwer, C. D. A., Koek, G. H., Schaper, N. C., & Isaacs, A. J. (2019) · Hepatology Communications · doi:10.1002/hep4.1319 · Cited by 53
HDL flux is higher in patients with nonalcoholic fatty liver disease
McCullough, A. J., Previs, S. F., Dasarathy, J., Lee, K., Ösme, A., Kim, C., Ilchenko, S., Lorkowski, S. W., Smith, J. D., Dasarathy, S., et al. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00193.2019 · Cited by 53
Huang, X., Shi, G., Devbhandari, R. P., Ke, A., Wang, Y., Wang, X., Wang, Z., Shi, Y., Xiao, Y., Ding, Z., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032775 · Cited by 51
Hao, Y., Zhou, J., Zhou, M., Ma, X., Lu, Z., Gao, M., Pan, X., Tang, J., Bao, Y., & Jia, W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072345 · Cited by 50
The association between liver fat and systemic calcified atherosclerosis
Koo, B. K., Allison, M., Criqui, M. H., Denenberg, J. O., & Criqui, M. H. (2019) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2019.03.044 · Cited by 47
Schneck, A.-S., Anty, R., Patouraux, S., Bonnafous, S., Rousseau, D., Lebeaupin, C., Bailly‐Maitre, B., Sans, A., Tran, A., Gugenheim, J., et al. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00344 · Cited by 46
Santo, S. M. S. E., Pires, N. M., Boesten, L. S. M., Gerritsen, G., Bovenschen, N., van Dijk, K. W., Jukema, J. W., Princen, H. M. G., Bensadoun, A., Li, W., et al. (2004) · Blood · doi:10.1182/blood-2003-11-4051 · Cited by 45
Lee, H. J., Lee, C. H., Kim, S., Hwang, S. Y., Hong, H. C., Choi, H. Y., Chung, H. S., Yoo, H. J., Seo, J. A., Kim, S. G., et al. (2016) · Metabolism · doi:10.1016/j.metabol.2016.11.004 · Cited by 45
Oni, E., Budoff, M. J., Zeb, I., Dong, L., Veledar, E., Polak, J. F., Blankstein, R., Wong, N. D., Blaha, M. J., Agatston, A. S., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.05.028 · Cited by 44
Zhang, Y., Li, S., Donelan, W., Xie, C., Wang, H., Wu, Q., Purich, D. L., Reeves, W. H., Tang, D., & Yang, L.-J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2015.11.003 · Cited by 43
Xin, Z., Zhu, Y., Wang, S., Liu, S., Xu, M., Wang, T., Lu, J., Chen, Y., Zhao, Z., Wang, W., et al. (2019) · Liver International · doi:10.1111/liv.14322 · Cited by 42
García‐Monzón, C., Petrov, P., Rey, E., Marañón, P., Pozo-Maroto, E. D., Guzmán, C., de Cía, J. R., Casado-Collado, A. J., Vargas‐Castrillón, J., Sáez, A., et al. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.07.028 · Cited by 41
Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease
Poulsen, M. K., Nellemann, B., Stødkilde-Jørgensen, H., Pedersen, S. B., Grønbæk, H., & Nielsen, S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3476 · Cited by 39
Zhou, M., Learned, R. M., Rossi, S. J., Tian, H., DePaoli, A. M., & Ling, L. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m089961 · Cited by 39
Niu, T.-H., Jiang, M., Xin, Y.-N., Jiang, X.-J., Lin, Z.-H., & Xuan, S.-Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i13.3655 · Cited by 38
Barchetta, I., Cimini, F. A., Chiappetta, C., Bertoccini, L., Ceccarelli, V., Capoccia, D., Gaggini, M., Cristofano, C. D., Rocca, C. D., Silecchia, G., et al. (2020) · Liver International · doi:10.1111/liv.14554 · Cited by 38
Moon, S. H., Noh, T. S., Cho, Y. S., Hong, S. P., Hyun, S. H., Choi, J. Y., Kim, B., & Lee, K.-H. (2014) · Angiology · doi:10.1177/0003319714537872 · Cited by 37
Lucero, D., Zago, V., Lopez, G. I., Graffigna, M., López, G. H., Fainboim, H. A., Miksztowicz, V., Rosso, L. A. G., Belli, S., Levalle, O. A., et al. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.12.012 · Cited by 36
Hamlin, A. N., Chinnarasu, S., Ding, Y., Xian, X., Herz, J., Jaeschke, A., & Hui, D. Y. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.001952 · Cited by 36
Labenz, C., Prochaska, J. H., Huber, Y., Nagel, M., Straub, B. K., Wild, P. S., Galle, P. R., & Schattenberg, J. M. (2019) · Hepatology Communications · doi:10.1002/hep4.1428 · Cited by 36
Yan, X., Gou, Z., Li, Y., Wang, Y., Zhu, J., Xu, G., & Zhang, Q. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0846-x · Cited by 35
Park, H. E., Lee, H., Choi, S., Kwak, M., Yang, J. I., Yim, J. Y., & Chung, G. E. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1516-5 · Cited by 34
Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality
Shahab, O., Biswas, R., Paik, J. M., Bush, H., Golabi, P., & Younossi, Z. M. (2018) · Hepatology Communications · doi:10.1002/hep4.1241 · Cited by 33
Hong, B. S., Liu, J., Zheng, J., Ke, W., Huang, Z., Wan, X., He, X., Xiao, H., & Li, Y. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12792 · Cited by 32
Zhang, R.-N., Zheng, R.-D., Mi, Y., Zhou, D., Shen, F., Chen, G., Zhu, C., Pan, Q., & Fan, J. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4120-7 · Cited by 29
Rüschenbaum, S., Schwarzkopf, K. M., Friedrich‐Rust, M., Seeger, F. H., Schoelzel, F., Martinez, Y., Zeuzem, S., Bojunga, J., & Lange, C. M. (2018) · Hepatology Communications · doi:10.1002/hep4.1183 · Cited by 29
Wan, S., Kuipers, F., Havinga, R., Ando, H., Vance, D. E., Jacobs, R. L., & van der Veen, J. N. (2019) · Hepatology Communications · doi:10.1002/hep4.1302 · Cited by 28
Corey, K. E., Wilson, L., Altınbaş, A., Yates, K. P., Kleiner, D. E., Chung, R. T., Krauss, R. M., & Chalasani, N. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15216 · Cited by 28
Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: new evidence, new challenges
Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2017) · Hepatology · doi:10.1002/hep.28960 · Cited by 26
Harada, P. H. N., Benseñor, I. M., Drager, L. F., Goulart, A. C., Mill, J. G., & Lotufo, P. A. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.02.005 · Cited by 23
Bariatric surgery, lipoprotein metabolism and cardiovascular risk
Tailleux, A., Rouskas, K., Pattou, F. N., & Staels, B. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000197 · Cited by 22
Self-citationKäräjämäki, A. J., Hukkanen, J., Kauma, H., Kesäniemi, Y. A., & Ukkola, O. H. (2019) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2019.1700428 · Cited by 22
APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice
Cheng, X., Yamauchi, J., Lee, S., Zhang, T., Gong, Z., Muzumdar, R. H., Qu, S., & Dong, H. H. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.765917 · Cited by 21
Plasma Betatrophin Levels and Carotid Atherosclerosis
Niki, H., Kishimoto, Y., Saita, E., Ohmori, R., Kondo, K. N., & Momiyama, Y. (2019) · Disease Markers · doi:10.1155/2019/4214650 · Cited by 9
Reply to “statins and non-alcoholic steatohepatitis”
Barb, D., & Cusi, K. J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.10.004 · Cited by 7
Cited by
PPAR control of metabolism and cardiovascular functions
Montaigne, D., Butruille, L., & Staels, B. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00569-6 · Cited by 942
Self-citationCurrent status and future trends of the global burden of MASLD
Miao, L., Targher, G., Byrne, C. D., Cao, Y.-Y., & Zheng, M.-H. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.02.007 · Cited by 781
Metabolic-associated fatty liver disease and lipoprotein metabolism
Heeren, J., & Scheja, L. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101238 · Cited by 646
Guo, X., Yin, X., Liu, Z., & Wang, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415489 · Cited by 412
Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
Borén, J., Taskinen, M.-R., Björnson, E., & Packard, C. J. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00676-y · Cited by 315
Metadata
- Authors
- Deprince, A., Haas, J. T., & Staels, B.
- Venue
- Molecular Metabolism
- Publisher
- Elsevier BV
- Published
- 2020-12
- Volume
- 42
- Pages
- 101092
- ISSN
- 2212-8778 (ISSN-L)
- OpenAlex
- W3091243730
- Cited by
- 554
- References
- 188
- FWCI
- 32.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.